Today's Trend
Esperion Therapeutics, Inc. (NASDAQ: ESPR) — Shares moved higher today after an announced take‑private deal; trading saw extreme volume and unusual options activity, while multiple shareholder law firms immediately opened investigations into the fairness of the transaction, creating litigation risk that could affect closing terms or timing.
- Archimed agreed to acquire Esperion in a deal valuing the company at as much as ~$1.1 billion; shareholders are to receive $3.16 per share in cash plus the right to participate in up to $100 million of contingent milestone payments — the bid is the primary catalyst lifting the stock. Article Title Article Title
- HC Wainwright reaffirmed a "neutral" rating and set a $3.16 price target — the PT matches the deal cash price, effectively signaling analyst alignment with the offer price but leaving little upside under the transaction. Article Title
- Trading was temporarily halted ahead of the announcement for "news pending," consistent with a material corporate event; halts are routine but can compress post‑halt volatility. (Internal trading halt notice)
- Unusual options activity: roughly 7,568 calls were bought — about a 212% increase versus typical daily call volume — indicating speculative or arbitrage positioning around the deal. This can amplify intraday moves but doesn’t change deal economics. (Options flow report)
- Multiple shareholder‑rights law firms (Monteverde & Associates/M&A Class Action Firm, Ademi LLP, and Halper Sadeh LLC) have opened investigations alleging Esperion shareholders may not be receiving a fair price, which could lead to litigation, a negotiated price revision, or delays to closing. Article Title Article Title Article Title
What investors should watch next: (1) any formal shareholder litigation or proxy litigation filings that could seek a higher price or injunctions; (2) comments from Esperion or Archimed on timing and definitive agreements; and (3) regulatory or antitrust steps if applicable. The deal price of $3.16 is the immediate valuation floor for public shareholders, but litigation or renegotiation could change outcomes.